-
Je něco špatně v tomto záznamu ?
Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses
T. Brodowicz, I. Lang, Z. Kahan, R. Greil, S. Beslija, SM. Stemmer, B. Kaufman, L. Petruzelka, A. Eniu, R. Anghel, K. Koynov, D. Vrbanec, T. Pienkowski, B. Melichar, S. Spanik, S. Ahlers, D. Messinger, MJ. Inbar, C. Zielinski,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu klinické zkoušky, fáze III, časopisecké články, randomizované kontrolované studie, práce podpořená grantem
NLK
Free Medical Journals
od 1947 do Před 1 rokem
Freely Accessible Journals
od 1947 do Před 1 rokem
PubMed Central
od 1947 do Před 1 rokem
Europe PubMed Central
od 1947 do Před 1 rokem
ProQuest Central
od 2000-01-01 do 2017-12-31
Open Access Digital Library
od 1947-01-01
Open Access Digital Library
od 1999-01-01
Medline Complete (EBSCOhost)
od 1999-01-01 do 2015-11-17
Nursing & Allied Health Database (ProQuest)
od 2000-01-01 do 2017-12-31
Health & Medicine (ProQuest)
od 2000-01-01 do 2017-12-31
Public Health Database (ProQuest)
od 2000-01-01 do 2017-12-31
PubMed
25268370
DOI
10.1038/bjc.2014.504
Knihovny.cz E-zdroje
- MeSH
- dospělí MeSH
- humanizované monoklonální protilátky aplikace a dávkování škodlivé účinky MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory prsu chemie farmakoterapie mortalita MeSH
- přežití bez známek nemoci MeSH
- protokoly protinádorové kombinované chemoterapie terapeutické užití MeSH
- receptor erbB-2 analýza MeSH
- rizikové faktory MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
BACKGROUND: The randomised phase III TURANDOT trial compared first-line bevacizumab-paclitaxel (BEV-PAC) vs bevacizumab-capecitabine (BEV-CAP) in HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). The interim analysis revealed no difference in overall survival (OS; primary end point) between treatment arms; however, progression-free survival (PFS) and objective response rate were significantly superior with BEV-PAC. We sought to identify patient populations that may be most appropriately treated with one or other regimen. METHODS: Patients with HER2-negative LR/mBC who had received no prior chemotherapy for advanced disease were randomised to either BEV-PAC (bevacizumab 10 mg kg(-1) days 1 and 15 plus paclitaxel 90 mg m(-2) days 1, 8 and 15 q4w) or BEV-CAP (bevacizumab 15 mg kg(-1) day 1 plus capecitabine 1000 mg m(-2) bid days 1-14 q3w). The study population was categorised into three cohorts: triple-negative breast cancer (TNBC), high-risk hormone receptor-positive (HR+) and low-risk HR+. High- and low-risk HR+ were defined, respectively, as having ⩾2 vs ⩽1 of the following four risk factors: disease-free interval ⩽24 months; visceral metastases; prior (neo)adjuvant anthracycline and/or taxane; and metastases in ⩾3 organs. RESULTS: The treatment effect on OS differed between cohorts. Non-significant OS trends favoured BEV-PAC in the TNBC cohort and BEV-CAP in the low-risk HR+ cohort. In all three cohorts, there was a non-significant PFS trend favouring BEV-PAC. Grade ⩾3 adverse events were consistently less common with BEV-CAP. CONCLUSIONS: A simple risk factor index may help in selecting bevacizumab-containing regimens, balancing outcome, safety profile and patient preference. Final OS results are expected in 2015 (ClinicalTrials.gov NCT00600340).
3rd Medical Department Paracelsus Medical University Hospital Salzburg and AGMT Salzburg Austria
Biometrics IST GmbH Soldnerstrasse 1 68219 Mannheim Germany
Breast Oncology Institute Sheba Medical Center 52621 Tel Hashomer Ramat Gan Israel
Davidoff Center Rabin Medical Center Kaplan Street Petah Tiqwa 49100 Israel
Department of Medical Oncology Hospital Serdika 6 Damyan Gruev street 1303 Sofia Bulgaria
Department of Oncology Palacký University Medical School 1 P Pavlova 6 775 20 Olomouc Czech Republic
Department of Oncotherapy University of Szeged H 6720 Szeged Korányi fasor 12 H 6720 Szeged Hungary
Oncology Department European Health Centre Otwock ul Borowa 14 18 04 500 Otwock Poland
Oncology Division Tel Aviv Sourasky Medical Center 6 Weizman Street Tel Aviv 64239 Israel
Ráth György u 7 9 National Institute of Oncology H 1122 Budapest Hungary
St Elisabeth Cancer Institute Heydukova 10 812 50 Bratislava Slovak Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15014042
- 003
- CZ-PrNML
- 005
- 20150424103617.0
- 007
- ta
- 008
- 150420s2014 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/bjc.2014.504 $2 doi
- 035 __
- $a (PubMed)25268370
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Brodowicz, T $u Clinical Division of Oncology and Department of Medicine I, Medical University of Vienna and CECOG, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
- 245 10
- $a Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses / $c T. Brodowicz, I. Lang, Z. Kahan, R. Greil, S. Beslija, SM. Stemmer, B. Kaufman, L. Petruzelka, A. Eniu, R. Anghel, K. Koynov, D. Vrbanec, T. Pienkowski, B. Melichar, S. Spanik, S. Ahlers, D. Messinger, MJ. Inbar, C. Zielinski,
- 520 9_
- $a BACKGROUND: The randomised phase III TURANDOT trial compared first-line bevacizumab-paclitaxel (BEV-PAC) vs bevacizumab-capecitabine (BEV-CAP) in HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). The interim analysis revealed no difference in overall survival (OS; primary end point) between treatment arms; however, progression-free survival (PFS) and objective response rate were significantly superior with BEV-PAC. We sought to identify patient populations that may be most appropriately treated with one or other regimen. METHODS: Patients with HER2-negative LR/mBC who had received no prior chemotherapy for advanced disease were randomised to either BEV-PAC (bevacizumab 10 mg kg(-1) days 1 and 15 plus paclitaxel 90 mg m(-2) days 1, 8 and 15 q4w) or BEV-CAP (bevacizumab 15 mg kg(-1) day 1 plus capecitabine 1000 mg m(-2) bid days 1-14 q3w). The study population was categorised into three cohorts: triple-negative breast cancer (TNBC), high-risk hormone receptor-positive (HR+) and low-risk HR+. High- and low-risk HR+ were defined, respectively, as having ⩾2 vs ⩽1 of the following four risk factors: disease-free interval ⩽24 months; visceral metastases; prior (neo)adjuvant anthracycline and/or taxane; and metastases in ⩾3 organs. RESULTS: The treatment effect on OS differed between cohorts. Non-significant OS trends favoured BEV-PAC in the TNBC cohort and BEV-CAP in the low-risk HR+ cohort. In all three cohorts, there was a non-significant PFS trend favouring BEV-PAC. Grade ⩾3 adverse events were consistently less common with BEV-CAP. CONCLUSIONS: A simple risk factor index may help in selecting bevacizumab-containing regimens, balancing outcome, safety profile and patient preference. Final OS results are expected in 2015 (ClinicalTrials.gov NCT00600340).
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a humanizované monoklonální protilátky $x aplikace a dávkování $x škodlivé účinky $7 D061067
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
- 650 _2
- $a nádory prsu $x chemie $x farmakoterapie $x mortalita $7 D001943
- 650 _2
- $a přežití bez známek nemoci $7 D018572
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a receptor erbB-2 $x analýza $7 D018719
- 650 _2
- $a rizikové faktory $7 D012307
- 655 _2
- $a klinické zkoušky, fáze III $7 D017428
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Lang, I $u Ráth György u. 7-9, National Institute of Oncology, H-1122 Budapest, Hungary.
- 700 1_
- $a Kahan, Z $u Department of Oncotherapy, University of Szeged, H-6720 Szeged, Korányi fasor 12, H-6720 Szeged, Hungary.
- 700 1_
- $a Greil, R $u IIIrd Medical Department, Paracelsus Medical University Hospital Salzburg and AGMT, Salzburg, Austria.
- 700 1_
- $a Beslija, S $u Institute of Oncology, Clinical Center, University of Sarajevo, Bolnicka 27, 71000 Sarajevo, Bosnia and Herzegovina.
- 700 1_
- $a Stemmer, S M $u Davidoff Center, Rabin Medical Center, Kaplan Street, Petah Tiqwa 49100, Israel.
- 700 1_
- $a Kaufman, B $u Breast Oncology Institute, Sheba Medical Center, 52621 Tel Hashomer, Ramat-Gan, Israel.
- 700 1_
- $a Petruzelka, L $u Department of Oncology, First Faculty of Medicine and General Teaching Hospital, Charles University Prague, U Nemocnice 2, 128 08 Prague 2, Czech Republic.
- 700 1_
- $a Eniu, A $u Department of Breast Tumors, Cancer Institute Ion Chiricuţă, Republicii 34-36, 400015 Cluj-Napoca, Romania.
- 700 1_
- $a Anghel, R $u University of Medicine and Pharmacy Bucharest, Soseaua Fundeni, Nr 252, Sector 2, Bucharest 022328, Romania. $7 gn_A_00006978
- 700 1_
- $a Koynov, K $u Department of Medical Oncology, Hospital Serdika, 6 Damyan Gruev street, 1303 Sofia, Bulgaria.
- 700 1_
- $a Vrbanec, D $u Department of Medical Oncology, University Hospital Zagreb-Rebro, Medical University of Zagreb, Kispaticeva 12, 10000 Zagreb, Croatia.
- 700 1_
- $a Pienkowski, T $u Oncology Department, European Health Centre Otwock, ul. Borowa 14/18, 04-500 Otwock, Poland.
- 700 1_
- $a Melichar, B $u Department of Oncology, Palacký University Medical School, I. P. Pavlova 6, 775 20 Olomouc, Czech Republic.
- 700 1_
- $a Spanik, S $u St Elisabeth Cancer Institute, Heydukova 10, 812 50 Bratislava, Slovak Republic.
- 700 1_
- $a Ahlers, S $u Biometrics, IST GmbH, Soldnerstrasse 1, 68219 Mannheim, Germany. $7 gn_A_00002381
- 700 1_
- $a Messinger, D $u Biometrics, IST GmbH, Soldnerstrasse 1, 68219 Mannheim, Germany.
- 700 1_
- $a Inbar, M J $u Oncology Division, Tel Aviv Sourasky Medical Center, 6 Weizman Street, Tel Aviv 64239, Israel.
- 700 1_
- $a Zielinski, C $u Clinical Division of Oncology and Department of Medicine I, Medical University of Vienna and CECOG, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
- 773 0_
- $w MED00009369 $t British journal of cancer $x 1532-1827 $g Roč. 111, č. 11 (2014), s. 2051-7
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25268370 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20150420 $b ABA008
- 991 __
- $a 20150424103918 $b ABA008
- 999 __
- $a ok $b bmc $g 1071623 $s 896920
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 111 $c 11 $d 2051-7 $i 1532-1827 $m British journal of cancer $n Br J Cancer $x MED00009369
- LZP __
- $a Pubmed-20150420
